News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Year: 2018

Epigenomics AG Announces 2018 Third Quarter and Nine Months Financial Results

PDF Berlin (Germany) and San Diego, CA (U.S.A.), November 7, 2018 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) today announced its financial results for the third quarter and the nine months 2018 ending September 30. Recent operational highlights -In September 2018, U.S. Congress urged the Centers of Medicare & Medicaid Services (CMS) to […]

Read more

Epigenomics AG Announces Veterans Administration’s Adherence Study using Epi proColon® Colorectal Cancer Screening Blood Test

PDF Berlin (Germany) and San Diego, CA (U.S.A.), October 31, 2018 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY) today announced the Veterans Administration – New York Harbor Healthcare System (VA-Manhattan) is commencing a study to assess the adherence impact of offering a blood-based colorectal cancer screening test and colonoscopy completion in patients who have refused […]

Read more

Epigenomics AG obtains CE Mark for Liquid Biopsy Test for Liver Cancer Detection

PDF – CE Mark for liver cancer blood test enables commercialization in Europe – Prospective U.S. trial for FDA submission to be initiated in 2019 – Investigating optimal path for CFDA approval in China Berlin (Germany) and San Diego, CA (U.S.A.), October 29, 2018 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY) today announced that it […]

Read more

Epigenomics AG successfully completes capital increase; gross proceeds of EUR 22.3 million

PDF Publication of Inside Information according to Article 17 MAR Berlin, October 23, 2018 – Epigenomics AG (FSE: ECX; OTCQX: EPGNY) (“Company”) has fully placed the new shares from the capital increase resolved on October 7, 2018 of up to EUR 12,007,180 (corresponds to 50% of the existing share capital). Accordingly, the Company’s share capital […]

Read more

Centers for Medicare & Medicaid Services publish final rate of $192 for Epigenomics’ colorectal cancer screening blood test Epi proColon®

PDF Berlin (Germany) and San Diego, CA (U.S.A.), October 22, 2018 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) today announced that the Centers for Medicare & Medicaid Services (CMS) published a final rate of $192 for Epi proColon, the first and only FDA-approved blood test for colorectal cancer screening. This announcement confirms the […]

Read more

Epigenomics AG sets subscription price at EUR 1.86 per new share

PDF Publication of Inside Information according to Article 17 MAR Berlin, October 16, 2018 – The Executive Board of Epigenomics AG (FSE: ECX; OTCQX: EPGNY) (“Company”) resolved today, with approval of the Supervisory Board, to set the subscription price per new share at EUR 1.86 as part of the capital increase resolved on October 7, […]

Read more